

## Anti-Siglec-2/CD22 Antibody (Inotuzumab-MMAE)

### Introduction


Andecaliximab is a biopharmaceutical targeting matrix metalloproteinase 9 (Andecaliximab is a recombinant IgG4 monoclonal antibody against MMP9. Andecaliximab has shown anti-fibrotic efficacy in a mouse model of idiopathic pulmonary fibrosis. Andecaliximab can be used in the study of gastric adenocarcinoma and idiopathic pulmonary fibrosis (IPF).

### Product parameters

Alternative Names	AB0045, GS-5745
Target Accession	P20273
Target	Siglec-2 / CD22
CAS number	1518996-49-0
Molecular Weight	145 kDa
Host	CHO
Reactivity	Human
Conjugation	MMAE
Form	Liquid
Concentration	See label
Buffer System	100 mM Pro 20 mM Arg pH 5.0. No preservative!
Clonality	Monoclonal
Purification	Protein A
Isotype	IgG4
Application	ELISA, FACS, Kinetics, Functional assay, Animal Model
Biological activity	Human Siglec-2 / CD22 HEK293 Cell Line were stained with Anti-Siglec-2/CD22 Antibody (Inotuzumab-MMAE) and negative control protein respectively, washed and then followed by PE and analyzed with FACS, The EC50 is 0.16 µg/mL.
Endotoxin	Less than 0.1 EU/ug determined by LAL method.
Sterilization	0.2 µM filtered
Reconstitution	For reconstitution, we recommend adding sterile, distilled water to achieve a final antibody concentration. Gently shake it to solubilize the protein completely. Do not vortex.
Shipping	Dry ice
Storage	-80°C
Expiration Date	2 years

## Note

1. This product is for scientific research use only.



**APEx BIO Technology**

**[www.apexbt.com](http://www.apexbt.com)**

7505 Fannin street, Suite 410, Houston, TX 77054.

Tel: +1-832-696-8203 | Fax: +1-832-641-3177 | Email: [info@apexbt.com](mailto:info@apexbt.com)

